This menu provides the list of EV proteins identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Protein name UniProt accession Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Proteomics. 2008 Jun;8(12):2430-46. doi: 10.1002/pmic.200701029.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Proteomics. 2008 Jun;8(12):2430-46. doi: 10.1002/pmic.200701029.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Proteomics. 2008 Jun;8(12):2430-46. doi: 10.1002/pmic.200701029.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomics characterization of cell membrane blebs in human retinal pigment epithelium cells.
Mol Cell Proteomics. 2009 Oct;8(10):2201-11. doi: 10.1074/mcp.M900203-MCP200. Epub 2009 Jun 29.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105The protein interaction network of extracellular vesicles derived from human colorectal cancer cells.
J Proteome Res. 2012 Feb 3;11(2):1144-51. doi: 10.1021/pr200842h. Epub 2012 Jan 9.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles.
PLoS One. 2012;7(7):e42064. doi: 10.1371/journal.pone.0042064. Epub 2012 Jul 27.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J Proteomics. 2013 Jan 16;80C:171-182. doi: 10.1016/j.jprot.2012.12.029.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J Proteomics. 2013 Jan 16;80C:171-182. doi: 10.1016/j.jprot.2012.12.029.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells.
Proteomics. 2013 Apr;13(7):1108-20. doi: 10.1002/pmic.201200531.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Characterization of multiple myeloma vesicles by label-free relative quantitation.
Proteomics. 2013 Oct;13(20):3013-29. doi: 10.1002/pmic.201300142.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells.
J Extracell Vesicles. 2012 Sep 11;1. doi: 10.3402/jev.v1i0.18704. eCollection 2012.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells.
J Extracell Vesicles. 2012 Sep 11;1. doi: 10.3402/jev.v1i0.18704. eCollection 2012.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes.
J Extracell Vesicles. 2012 Apr 16;1. doi: 10.3402/jev.v1i0.18396. eCollection 2012.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem Biophys Res Commun. 2014 Mar 21;445(4):694-701. doi: 10.1016/j.bbrc.2013.12.070. Epub 2014 Jan 14.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteins recruited to exosomes by tau overexpression implicate novel cellular mechanisms linking tau secretion with Alzheimer's disease.
J Alzheimers Dis. 2014;40 Suppl 1:S47-70. doi: 10.3233/JAD-132135.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Human thymic epithelial primary cells produce exosomes carrying tissue-restricted antigens.
Immunol Cell Biol. 2015 Mar 17. doi: 10.1038/icb.2015.33.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Oncotarget. 2015 Mar 12.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein.
Oncotarget. 2016 Apr 11. doi: 10.18632/oncotarget.8678.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Effective isolation of exosomes with polyethylene glycol from cell culture supernatant for in-depth proteome profiling.
Analyst. 2016 May 27.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Oncotarget. 2016 Aug 8. doi: 10.18632/oncotarget.11111.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Mycobacterium tuberculosis Infection Manipulates the Glycosylation Machinery and the N-Glycoproteome of Human Macrophages and their Microparticles.
J Proteome Res. 2016 Oct 19.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Mycobacterium tuberculosis Infection Manipulates the Glycosylation Machinery and the N-Glycoproteome of Human Macrophages and their Microparticles.
J Proteome Res. 2016 Oct 19.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Detailed Analysis of Protein Topology of Extracellular Vesicles-Evidence of Unconventional Membrane Protein Orientation.
Sci Rep. 2016 Nov 8;6:36338. doi: 10.1038/srep36338.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources.
J Extracell Vesicles. 2016 Nov 17;5:32570. doi: 10.3402/jev.v5.32570. eCollection 2016.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources.
J Extracell Vesicles. 2016 Nov 17;5:32570. doi: 10.3402/jev.v5.32570. eCollection 2016.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources.
J Extracell Vesicles. 2016 Nov 17;5:32570. doi: 10.3402/jev.v5.32570. eCollection 2016.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.
Proteomics. 2017 Jun 7. doi: 10.1002/pmic.201700103.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.
Proteomics. 2017 Jun 7. doi: 10.1002/pmic.201700103.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.
Proteomics. 2017 Jun 7. doi: 10.1002/pmic.201700103.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method.
J Extracell Vesicles. 2017 Apr 28;6(1):1313091. doi: 10.1080/20013078.2017.1313091. eCollection 2017.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method.
J Extracell Vesicles. 2017 Apr 28;6(1):1313091. doi: 10.1080/20013078.2017.1313091. eCollection 2017.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.		ENOG410XQRX156 / 0 / 156
Protein SET (HLA-DR-associated protein II) (Inhibitor of granzyme A-activated DNase) (IGAAD) (PHAPII) (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template-activating factor I) (TAF-I)Q01105Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.		ENOG410XQRX156 / 0 / 156
[1] [2]